NASDAQ:SRZN Surrozen (SRZN) Stock Price, News & Analysis $8.57 +0.04 (+0.47%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$8.53▼$8.9050-Day Range$8.38▼$11.4352-Week Range$4.50▼$16.19Volume3,195 shsAverage Volume13,462 shsMarket Capitalization$27.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Surrozen alerts: Email Address Ad Stansberry ResearchFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.Get our No. 1 stock (with 500%-plus upside potential) for this rare market event now. About Surrozen Stock (NASDAQ:SRZN)Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.Read More SRZN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRZN Stock News HeadlinesJune 12, 2024 | globenewswire.comSurrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt SignalingJune 10, 2024 | globenewswire.comSurrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in MilanJuly 27, 2024 | Stansberry Research (Ad)Former Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.June 4, 2024 | globenewswire.comSurrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated HepatitisMay 9, 2024 | globenewswire.comSurrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual MeetingMay 9, 2024 | investorplace.comSRZN Stock Earnings: Surrozen Beats EPS for Q1 2024May 8, 2024 | globenewswire.comSurrozen Provides First Quarter 2024 Financial Results and Business UpdateApril 18, 2024 | msn.comSurrozen files to sell 1.09M shares of common stock for holdersJuly 27, 2024 | Stansberry Research (Ad)Former Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.April 18, 2024 | msn.comSurrozen (SRZN) Price Target Decreased by 40.00% to 20.66April 10, 2024 | uk.investing.comSurrozen director Tim Kutzkey acquires $3m in company stockApril 3, 2024 | globenewswire.comSurrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary FibrosisApril 1, 2024 | msn.comU.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.60%April 1, 2024 | msn.comWhy Is Regenerative Medicine-Focused Surrozen Stock Trading Lower On Monday?April 1, 2024 | globenewswire.comSurrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq RulesApril 1, 2024 | globenewswire.comSurrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043February 8, 2024 | msn.comSurrozen Promotes Charles Williams to COO with CFO RoleJanuary 18, 2024 | finanznachrichten.deSurrozen, Inc.: Surrozen Provides Corporate Update on Clinical ProgramsSee More Headlines Receive SRZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SRZN CUSIPN/A CIK1824893 Webwww.consonancehfw.com Phone650-489-9000FaxN/AEmployees80Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-85.54% Return on Assets-71.86% Debt Debt-to-Equity RatioN/A Current Ratio5.18 Quick Ratio5.18 Sales & Book Value Annual Sales$12.50 million Price / Sales2.19 Cash FlowN/A Price / Cash FlowN/A Book Value$18.39 per share Price / Book0.47Miscellaneous Outstanding Shares3,200,000Free Float1,807,000Market Cap$27.42 million OptionableNot Optionable Beta0.89 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Craig C. Parker M.B.A. (Age 62)CEO, President & Director Comp: $825.32kMr. Charles Williams (Age 44)CFO, COO & Corporate Secretary Comp: $611.03kDr. Li Yang Ph.D. (Age 55)Executive Vice President of Research Comp: $535.46kDr. K. Christopher Garcia Ph.D.Co-Founder & Member of Scientific Advisory BoardDr. Roeland Nusse Ph.D. (Age 74)Co-Founder & Member of Scientific Advisory Board Dr. Calvin Kuo M.D.Ph.D., Co-Founder & Member of Scientific AdvisorEsther JhunControllerMore ExecutivesKey CompetitorsOCA AcquisitionNASDAQ:OCAXOramed PharmaceuticalsNASDAQ:ORMPAclaris TherapeuticsNASDAQ:ACRSSagimet BiosciencesNASDAQ:SGMTDBV TechnologiesNASDAQ:DBVTView All CompetitorsInsidersTim KutzkeyBought 193,548 shares on 4/4/2024Total: $3.00 M ($15.50/share)View All Insider Transactions SRZN Stock Analysis - Frequently Asked Questions How have SRZN shares performed this year? Surrozen's stock was trading at $9.40 at the start of the year. Since then, SRZN stock has decreased by 8.8% and is now trading at $8.57. View the best growth stocks for 2024 here. How were Surrozen's earnings last quarter? Surrozen, Inc. (NASDAQ:SRZN) released its earnings results on Wednesday, May, 8th. The company reported ($4.24) earnings per share for the quarter, beating analysts' consensus estimates of ($4.25) by $0.01. When did Surrozen's stock split? Shares of Surrozen reverse split on the morning of Thursday, December 14th 2023. The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Surrozen? Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SRZN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surrozen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surrozen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRZN Stock Alerts